Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503352 | 0.76 | ADORA2B (0.62) | ADORA2A | |
| SCHEMBL6508012 | 0.70 | ADORA2B (0.65) | ADORA2A | |
| SCHEMBL10544630 | 0.69 | CYSLTR1 (0.84) | PDE10ACYP1A2CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL12169160 | 0.69 | PDE10A (0.64) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL1419982 | 0.69 | PDE10A (0.64) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL9199452 | 0.68 | GPBAR1 (0.59) | PDE10ACYP1A2CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8001866 | 0.66 | CYSLTR1 (0.74) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL6502281 | 0.66 | ADORA2B (0.59) | PDE10AADORA2A | |
| SCHEMBL10547475 | 0.66 | CYSLTR1 (0.76) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL10547998 | 0.66 | CYSLTR1 (1.00) | PDE10ACYSLTR1CYSLTR2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | PDE10A 795/4885CYP1A2 44/4885CYSLTR1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.